401 related articles for article (PubMed ID: 31473910)
1. Characteristics and Prognosis of Talaromyces marneffei Infection in Non-HIV-Infected Children in Southern China.
Guo J; Li BK; Li TM; Wei FL; Fu YJ; Zheng YQ; Pan KS; Huang CY; Cao CW
Mycopathologia; 2019 Dec; 184(6):735-745. PubMed ID: 31473910
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and Prognosis of Talaromyces marneffei Infection in HIV-positive Children in Southern China.
Xue X; Zou J; Fang W; Liu X; Chen M; Arastehfar A; Ilkit M; Zheng Y; Qin J; Peng Z; Hu D; Liao W; Pan W
Mycopathologia; 2022 Jun; 187(2-3):169-180. PubMed ID: 35157189
[TBL] [Abstract][Full Text] [Related]
3. Successful voriconazole treatment of Talaromyces marneffei infection in an HIV-negative patient with osteolytic lesions.
Ge Y; Xu Z; Hu Y; Huang M
J Infect Chemother; 2019 Mar; 25(3):204-207. PubMed ID: 30195473
[TBL] [Abstract][Full Text] [Related]
4. Administration of Voriconazole in Disseminated Talaromyces (Penicillium) Marneffei Infection: A Retrospective Study.
Ouyang Y; Cai S; Liang H; Cao C
Mycopathologia; 2017 Jun; 182(5-6):569-575. PubMed ID: 28108867
[TBL] [Abstract][Full Text] [Related]
5. Talaromyces (Penicillium) marneffei infection in non-HIV-infected patients.
Chan JF; Lau SK; Yuen KY; Woo PC
Emerg Microbes Infect; 2016 Mar; 5(3):e19. PubMed ID: 26956447
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility profile of echinocandins, azoles and amphotericin B against yeast phase of Talaromyces marneffei isolated from HIV-infected patients in Guangdong, China.
Lei HL; Li LH; Chen WS; Song WN; He Y; Hu FY; Chen XJ; Cai WP; Tang XP
Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1099-1102. PubMed ID: 29536323
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of Talaromyces marneffei infection in a kidney transplant recipient with voriconazole followed by itraconazole for the first time.
Li Y; Tang M; Sun S; Hu Q; Deng S
J Mycol Med; 2022 Mar; 32(1):101214. PubMed ID: 34763148
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole Versus Amphotericin B as Induction Therapy for Talaromycosis in HIV/AIDS Patients: A Retrospective Study.
Huang W; Li T; Zhou C; Wei F; Cao C; Jiang J
Mycopathologia; 2021 May; 186(2):269-276. PubMed ID: 33616828
[TBL] [Abstract][Full Text] [Related]
9. Effects of Talaromyces marneffei infection on mortality of HIV/AIDS patients in southern China: a retrospective cohort study.
Jiang J; Meng S; Huang S; Ruan Y; Lu X; Li JZ; Wu N; Huang J; Xie Z; Liang B; Deng J; Zhou B; Chen X; Ning C; Liao Y; Wei W; Lai J; Ye L; Wu F; Liang H
Clin Microbiol Infect; 2019 Feb; 25(2):233-241. PubMed ID: 29698815
[TBL] [Abstract][Full Text] [Related]
10. AIDS-associated Talaromyces marneffei central nervous system infection in patients of southwestern China.
Li YY; Dong RJ; Shrestha S; Upadhyay P; Li HQ; Kuang YQ; Yang XP; Zhang YG
AIDS Res Ther; 2020 May; 17(1):26. PubMed ID: 32456686
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics, rapid identification, molecular epidemiology and antifungal susceptibilities of Talaromyces marneffei infections in Shenzhen, China.
Lau SKP; Xing F; Tsang CC; Tang JYM; Tan YP; Ye H; Lau RWT; Chen JHK; Lo SKF; Woo PCY
Mycoses; 2019 May; 62(5):450-457. PubMed ID: 30597630
[TBL] [Abstract][Full Text] [Related]
12. Disseminated Penicillium marneffei infection in human immunodeficiency virus-infected children.
Sirisanthana V; Sirisanthana T
Pediatr Infect Dis J; 1995 Nov; 14(11):935-40. PubMed ID: 8584358
[TBL] [Abstract][Full Text] [Related]
13. Talaromycosis (Penicilliosis) Due to Talaromyces (Penicillium) marneffei: Insights into the Clinical Trends of a Major Fungal Disease 60 Years After the Discovery of the Pathogen.
Cao C; Xi L; Chaturvedi V
Mycopathologia; 2019 Dec; 184(6):709-720. PubMed ID: 31811603
[TBL] [Abstract][Full Text] [Related]
14. A case report of Talaromyces marneffei Oro-pharyngo-laryngitis: a rare manifestation of Talaromycosis.
Wongkamhla T; Chongtrakool P; Jitmuang A
BMC Infect Dis; 2019 Dec; 19(1):1034. PubMed ID: 31805893
[TBL] [Abstract][Full Text] [Related]
15. Prognosis and treatment effects of HIV-associated talaromycosis in a real-world patient cohort.
Klus J; Ly VT; Chan C; Le T
Med Mycol; 2021 Apr; 59(4):392-399. PubMed ID: 33644813
[TBL] [Abstract][Full Text] [Related]
16. A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis.
Le T; Kinh NV; Cuc NTK; Tung NLN; Lam NT; Thuy PTT; Cuong DD; Phuc PTH; Vinh VH; Hanh DTH; Tam VV; Thanh NT; Thuy TP; Hang NT; Long HB; Nhan HT; Wertheim HFL; Merson L; Shikuma C; Day JN; Chau NVV; Farrar J; Thwaites G; Wolbers M;
N Engl J Med; 2017 Jun; 376(24):2329-2340. PubMed ID: 28614691
[TBL] [Abstract][Full Text] [Related]
17. Disseminated Talaromyces marneffei infection presenting as multiple intestinal perforations and diffuse hepatic granulomatous inflammation in an infant with STAT3 mutation: a case report.
Pan M; Qiu Y; Zeng W; Tang S; Wei X; Zhang J
BMC Infect Dis; 2020 Jun; 20(1):394. PubMed ID: 32493232
[TBL] [Abstract][Full Text] [Related]
18. Peripheral immune profile of children with Talaromyces marneffei infections: a retrospective analysis of 21 cases.
Zeng Q; Jin Y; Yin G; Yang D; Li W; Shi T; Lu G; Huang L; Fan H
BMC Infect Dis; 2021 Mar; 21(1):287. PubMed ID: 33743629
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and risk factors for readmission in HIV-infected patients with Talaromyces marneffei infection.
Shi M; Qin Y; Chen S; Wei W; Meng S; Chen X; Li J; Li Y; Chen R; Su J; Yuan Z; Wang G; Qin Y; Ye L; Liang H; Xie Z; Jiang J
PLoS Negl Trop Dis; 2023 Oct; 17(10):e0011622. PubMed ID: 37816066
[TBL] [Abstract][Full Text] [Related]
20. Determinants of prognosis in Talaromyces marneffei infections with respiratory system lesions.
Qiu Y; Zhang JQ; Pan ML; Zeng W; Tang SD; Tan CM
Chin Med J (Engl); 2019 Aug; 132(16):1909-1918. PubMed ID: 31348027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
